2.99
price down icon0.33%   -0.010
after-market Dopo l'orario di chiusura: 2.99
loading

Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie

pulisher
Nov 05, 2024

Allogene Therapeutics to Present New Data Demonstrating the - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Allogene Therapeutics to Present New Data Demonstrating the Potential of Allo-316 in Heavily Pretreated Adult Patients with Cd70 Positive Advanced Renal Cell Carcinoma At the International Kidney Cancer Symposium and Society for Immunotherapy of Ca - Marketscreener.com

Nov 05, 2024
pulisher
Nov 04, 2024

Allogene Therapeutics (NASDAQ:ALLO) Stock Price Up 6.3%Still a Buy? - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Palisade Bio (NASDAQ:PALI) and Allogene Therapeutics (NASDAQ:ALLO) Critical Survey - Defense World

Nov 04, 2024
pulisher
Nov 04, 2024

Allogene Therapeutics Announces Participation in November Investor Conferences - StockTitan

Nov 04, 2024
pulisher
Nov 02, 2024

Allogene Therapeutics’ (ALLO) “Buy” Rating Reiterated at HC Wainwright - Defense World

Nov 02, 2024
pulisher
Oct 31, 2024

Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Allogene Therapeutics (ALLO) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Allogene shares hold buy rating as FDA grants RMAT to ALLO-316 - Investing.com Australia

Oct 31, 2024
pulisher
Oct 30, 2024

HC Wainwright Reiterates "Buy" Rating for Allogene Therapeutics (NASDAQ:ALLO) - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update - GlobeNewswire

Oct 30, 2024
pulisher
Oct 29, 2024

FDA grants RMAT status to Allogene's kidney cancer therapy By Investing.com - Investing.com South Africa

Oct 29, 2024
pulisher
Oct 29, 2024

FDA grants RMAT status to Allogene's kidney cancer therapy - Investing.com

Oct 29, 2024
pulisher
Oct 29, 2024

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

Allogene Therapeutics Receives FDA Regenerative Medicine - GlobeNewswire

Oct 29, 2024
pulisher
Oct 29, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

Allogene Therapeutics (NASDAQ:ALLO) Stock Price Up 6.6%Time to Buy? - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Allogene Therapeutics Inc (NASDAQ: ALLO) Stock Forecast: Could Pass $55 In A Year - Stocks Register

Oct 28, 2024
pulisher
Oct 24, 2024

Allogene Therapeutics (NASDAQ:ALLO) Shares Down 5.4%Should You Sell? - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

Research Analysts Offer Predictions for ALLO Q3 Earnings - MarketBeat

Oct 24, 2024
pulisher
Oct 22, 2024

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.

Oct 22, 2024
pulisher
Oct 22, 2024

Exchange Traded Concepts LLC Acquires 12,328 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World

Oct 22, 2024
pulisher
Oct 19, 2024

AQR Capital Management LLC Purchases Shares of 27,287 Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World

Oct 19, 2024
pulisher
Oct 18, 2024

Allogene Therapeutics (ALLO) Stock Surges Amid Biotechnology Sec - GuruFocus.com

Oct 18, 2024
pulisher
Oct 16, 2024

Wall Street analysts’ outlook for Allogene Therapeutics Inc (ALLO) - SETE News

Oct 16, 2024
pulisher
Oct 14, 2024

Allogene Therapeutics Inc [ALLO] Investment Guide: What You Need to Know - Knox Daily

Oct 14, 2024
pulisher
Oct 14, 2024

Allogene Therapeutics Inc’s Market Journey: Closing Strong at 2.65, Up 1.15 - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

The Allogene Therapeutics Inc (ALLO) had a good session last reading, didn’t it? - US Post News

Oct 14, 2024
pulisher
Oct 13, 2024

The Manufacturers Life Insurance Company Has $1.12 Million Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Oct 13, 2024
pulisher
Oct 12, 2024

126,628 Shares in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Purchased by Squarepoint Ops LLC - Defense World

Oct 12, 2024
pulisher
Oct 10, 2024

Taking a look at what insiders are doing to gauge the Allogene Therapeutics Inc (ALLO)’s direction - Knox Daily

Oct 10, 2024
pulisher
Oct 10, 2024

Ready to Jump After Recent Trade: Allogene Therapeutics Inc (ALLO) - SETE News

Oct 10, 2024
pulisher
Oct 09, 2024

Allogene Therapeutics Inc (ALLO) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle

Oct 09, 2024
pulisher
Oct 09, 2024

Dimensional Fund Advisors LP Increases Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Oct 09, 2024
pulisher
Oct 08, 2024

Allogene Therapeutics (ALLO) Sees 5% Stock Surge Amidst Biotech Sector Movement - GuruFocus.com

Oct 08, 2024
pulisher
Oct 07, 2024

Allogene Therapeutics Inc’s Market Journey: Closing Strong at 2.70, Up 3.45 - The Dwinnex

Oct 07, 2024
pulisher
Oct 04, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

Allogene Therapeutics Inc (ALLO) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Oct 03, 2024
pulisher
Oct 03, 2024

Allogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In Now - Insider Monkey

Oct 03, 2024
pulisher
Oct 02, 2024

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Act - GuruFocus.com

Oct 02, 2024
pulisher
Oct 02, 2024

Market Insights: Allogene Therapeutics Inc (ALLO)’s Notable Drop of -4.64, Closing at 2.67 - The Dwinnex

Oct 02, 2024
pulisher
Oct 02, 2024

You might want to take a look at Allogene Therapeutics Inc (ALLO) now - SETE News

Oct 02, 2024
pulisher
Oct 01, 2024

Allogene Therapeutics (NASDAQ:ALLO) Trading Down 6.4% - MarketBeat

Oct 01, 2024
pulisher
Sep 30, 2024

7 Best Rising Penny Stocks To Invest In Now - Insider Monkey

Sep 30, 2024
pulisher
Sep 30, 2024

Allogene Therapeutics (ALLO) Shares Dip 5.15% Amid Market Volati - GuruFocus.com

Sep 30, 2024
pulisher
Sep 30, 2024

Understanding the Risks of Investing in Allogene Therapeutics Inc (ALLO) - Knox Daily

Sep 30, 2024
pulisher
Sep 30, 2024

Did Allogene Therapeutics Inc (ALLO) perform well in the last session? - US Post News

Sep 30, 2024
pulisher
Sep 30, 2024

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference - GlobeNewswire

Sep 30, 2024
pulisher
Sep 30, 2024

Perceptive Advisors LLC Takes Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Sep 30, 2024
pulisher
Sep 29, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Bought by Renaissance Technologies LLC - MarketBeat

Sep 29, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Allogene stock navigates expanded rights and clinical milestones - Investing.com

Sep 27, 2024
pulisher
Sep 27, 2024

Allogene Therapeutics (ALLO) Stock Jumps by 5.15% - GuruFocus.com

Sep 27, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Allogene stock navigates expanded rights and clinical milestones By Investing.com - Investing.com South Africa

Sep 27, 2024
pulisher
Sep 27, 2024

Lynx1 Capital Management LP Invests $5.19 Million in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Sep 27, 2024
pulisher
Sep 26, 2024

Allogene reveals next-gen CAR T candidate for autoimmune disease - Investing.com India

Sep 26, 2024
pulisher
Sep 26, 2024

Allogene reveals next-gen CAR T candidate for autoimmune disease By Investing.com - Investing.com Canada

Sep 26, 2024
pulisher
Sep 26, 2024

Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence - GlobeNewswire

Sep 26, 2024
pulisher
Sep 26, 2024

Allogene Therapeutics to Present Pre-Clinical Data - GlobeNewswire

Sep 26, 2024
pulisher
Sep 25, 2024

A better buy-in window may exist right now for Allogene Therapeutics Inc (ALLO) - SETE News

Sep 25, 2024
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Capitalizzazione:     |  Volume (24 ore):